MedPage Today has been covering the San Francisco annual meeting of the AAO (American Academy of Ophthalmology) and filed this report following up on a two year study of gene therapy.
Patients with severe neovascular age-related macular degeneration (AMD) had long-term vision stabilization and anatomic improvement following a single treatment with an investigational gene therapy, a preliminary study showed.
Asked how long the therapy might allow patients to go without additional treatment, Dr. Jeffrey Heier, MD, of Ophthalmic Consultants of Boston, said some patients treated with RGX-314 have been followed almost 2 years without retreatment, and studies of other types of gene therapy have maintained efficacy for several years. "It remains to be seen, but it's certainly encouraging," he stated.
Read the full story on Gene Therapy.
Read the related story